


Serial No. 10/735,561  
Attorney Docket No. PC25627A

# AMENDMENTS TO THE CLAIMS

Claims 1-6 (canceled)

Claim 7 (currently amended): A method for treating fibromyalgia in a mammal, ~~including a human, the method~~ comprising administering to said mammal a therapeutically effective amount for treating fibromyalgia of a compound of formula



(3*S*,4*S*)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid or a pharmaceutically acceptable salt thereof wherein

~~R is hydrogen or a lower alkyl;~~


~~R<sup>1</sup> to R<sup>14</sup> are each independently selected from hydrogen, straight or branched alkyl of from 1 to 6 carbons, phenyl, benzyl, fluorine, chlorine, bromine, hydroxy, hydroxymethyl, amino, aminomethyl, trifluoromethyl, CO<sub>2</sub>H, CO<sub>2</sub>R<sup>15</sup>, CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CO<sub>2</sub>R<sup>15</sup>, OR<sup>15</sup> wherein R<sup>15</sup> is a straight or branched alkyl of from 1 to 6 carbons, phenyl, or benzyl, and R<sup>1</sup> to R<sup>8</sup> are not simultaneously hydrogen.~~

Claim 8 (canceled)

Claim 9 (currently amended): A method for treating fibromyalgia and a concomitant disorder in a mammal, ~~including a human, the method~~ comprising administering to said mammal a therapeutically effective amount for treating fibromyalgia and a concomitant disorder of a compound of formula

(Non-Final Amendment—page 2 of 8)

Serial No. 10/735,561  
Attorney Docket No. PC25627A



(3*S*,4*S*)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid or a pharmaceutically acceptable salt thereof wherein

~~R is hydrogen or a lower alkyl;~~

~~R<sup>1</sup> to R<sup>14</sup> are each independently selected from hydrogen, straight or branched alkyl of from 1 to 6 carbons, phenyl, benzyl, fluorine, chlorine, bromine, hydroxy, hydroxymethyl, amino, aminomethyl, trifluoromethyl, CO<sub>2</sub>H, CO<sub>2</sub>R<sup>15</sup>, CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CO<sub>2</sub>R<sup>15</sup>, OR<sup>15</sup>, wherein R<sup>15</sup> is a straight or branched alkyl of from 1 to 6 carbons, phenyl, or benzyl, and R<sup>1</sup> to R<sup>8</sup> are not simultaneously hydrogen, and wherein~~

said concomitant disorder is selected from migraine headaches, temporomandibular joint dysfunction, dysautonomia, endocrine dysfunction, dizziness, cold intolerance, chemical sensitivity, sicca symptoms, cognitive dysfunction, generalized anxiety disorder, premenstrual dysphoric dysthemia, irritable bowel syndrome, functional abdominal pain, neuropathic pain, and somatoform disorders, OCD, phobias, and PTSD.

**Claim 10 (canceled)**

**Claim 11 (currently amended):** The method according to claim 9 wherein said concomitant disorder is generalized anxiety disorder, premenstrual dysphoric disorder, or a somatoform disorder, and wherein the compound administered is (3S, 4S) (1-Aminomethyl-3,4-dimethyl-cyclopentyl) acetic acid.

(Non-Final Amendment—page 3 of 8)

Serial No. 10/735,561  
Attorney Docket No. PC25627A

Claim 12 (currently amended): The method according to 9 wherein said concomitant disorder is irritable bowel syndrome, functional abdominal pain, neuropathic pain, or migraine headache, and wherein the compound administered is ~~(3S, 4S) (1-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid~~.

Claims 13-16 (canceled)

(Non-Final Amendment—page 4 of 8)